🇺🇸 ACE inhibitor in United States
669 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 21 April 2025 – 21 April 2026
- Total reports: 669
Most-reported reactions
- Dyspnoea — 108 reports (16.14%)
- Hypotension — 82 reports (12.26%)
- Renal Failure Acute — 77 reports (11.51%)
- Blood Creatinine Increased — 69 reports (10.31%)
- Renal Failure — 68 reports (10.16%)
- Nausea — 63 reports (9.42%)
- Hypertension — 53 reports (7.92%)
- Diarrhoea — 52 reports (7.77%)
- Fatigue — 49 reports (7.32%)
- Asthenia — 48 reports (7.17%)
Other Cardiovascular approved in United States
Frequently asked questions
Is ACE inhibitor approved in United States?
ACE inhibitor does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for ACE inhibitor in United States?
University of Cambridge is the originator. The local marketing authorisation holder may differ — check the official source linked above.